Viral protein apoptin as a molecular tool and therapeutic bullet: Implications for cancer control

Future Virology

Volumn 2, Issue 5, 2007, Pages 519-527

  Visser, Astrid E ^a   Backendorf, Claude ^a   Noteborn, Mathieu ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Anaphase promoting complex; Anticancer therapy; Apoptin; Apoptosis; Cancer; Ceramide; Chicken anemia virus; Discovery; Drug targets; Pathway

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; APOPTIN; INTERLEUKIN 18; PHOSPHOTRANSFERASE; PLASMID DNA; PROTEIN P53; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; CANCER CONTROL; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; CARCINOGENESIS; CELL INTERACTION; CELL NUCLEUS; CIRCOVIRIDAE; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; FOWLPOX VIRUS; HUMAN; LIVER CELL CARCINOMA; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL;

ANIMALIA; CHICKEN ANEMIA VIRUS;

EID: 34648816237     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.5.519     Document Type: Review

References (51)

1. Noteborn MH: Apoptin acts as a tumor-specific killer: potentials for an antitumor therapy. Cell. Mol. Biol. (Noisy-le-grand) 51, 49-60 (2005).
2. Tavassoli M, Guelen L, Luxon BA, Gaken J: Apoptin: specific killer of tumor cells? Apoptosis 10, 717-724 (2005).
3. Danen-Van Oorschot AA, Fischer DF, Grimbergen JM et al.: Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl Acad. Sci. USA 94, 5843-5847 (1997).
4. Heilman DW, Teodoro JG, Green MR: Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J. Virol. 80, 7535-7545 (2006).
5. Zhang YH, Kooistra K, Pietersen A, Rohn JL, Noteborn MH: Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen. J. Virol. 78, 9965-9976 (2004).
6. Rohn JL, Zhang YH, Aalbers RI et al.: A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 277, 50820-50827 (2002).
7. Zhang YH, Letiveld SR, Kooistra K et al.: Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in a normal-cell-specific fashion. Exp. Cell Res. 289, 36-46 (2003).
8. Leliveld SR, Dame RT, Mommaas MA et al.: Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acids Res. 31, 4805-4813 (2003).
9. Janssen K, Hofmann TG, Jans DA, Hay RT, Schulze-Osthoff K, Fischer U: Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies. Oncogene 26, 1557-1566 (2007).
10. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M: TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 23, 1153-1165 (2004).
11. Danen-Van Oorschot AA, Zhang YH, Leliveld SR et al.: Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 278, 27729-27736 (2003).
12. Poon IK, Oro C, Dias MM, Zhang J, Jans DA: Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 65, 7059-7064 (2005).
13. Wagstaff KM, Jans DA: Intramolecular masking of nuclear localization signals: analysis of importin binding using a novel AlphaScreen-based method. Anal. Biochem. 348, 49-56 (2006).
14. Alvisi G, Poon IK, Jans DA: Tumor-specific nuclear targeting: promises for anticancer therapy? Drug Resist. Updat. 9, 40-50 (2006).
15. Rohn JL, Zhang YH, Leliveld SR et al.: Relevance of apoptin's integrity for its functional behavior. J. Virol. 79, 1337-1338 (2005).
16. Tolboom TC, Zhang YH, Henriquez NV et al.: Fibroblast-like synoviocytes from patients with rheumatoid arthritis are more sensitive to apoptosis induced by the viral protein, apoptin, than fibroblast-like synoviocytes from trauma patients. Clin. Exp. Rheumatol. 24, 142-147 (2006).
17. Everett RD, Chelbi-Alix MK: PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89 (6-7), 819-830 (2007).
18. Kerscher O: SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 8, 550-555 (2007).
19. Song Z, Wu M: Identification of a novel nucleolar localization signal and a degradation signal in Survivin-deltaEx3: a potential link between nucleolus and protein degradation. Oncogene 24, 2723-2734 (2005).
20. Pietersen A, Erkeland SJ, Rutjes SA, Philipsen S, Medema JP, Noteborn MH: Continuous apoptin expression in transgenic mice does not interfere with lymphocyte development and proliferation. J. Med. Mol. Biol. 2, 321-330 (2005).
21. Backendorf C, Visser AE, de Boer AG et al.: Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Ann. Rev. Pharm. Toxicol. (In Press).
22. Danen-van Oorschot AA, Voskamp P, Seelen MC et al.: Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 11, 564-573 (2004).
23. Majumder P, Chattopadhyay B, Mazumder A, Das P, Bhattacharyya NP: Induction of apoptosis in cells expressing exogenous Hippi, a molecular partner of huntingtin-interacting protein Hip1. Neurobiol. Dis. 22, 242-256 (2006).
24. Houde C, Dickinson RJ, Houtzager VM et al.: Hippi is essential for node cilia assembly and Sonic hedgehog signaling. Dev. Biol. 300, 523-533 (2006).
25. Cheng CM, Huang SP, Chang YF, Chung WY, Yuo CY: The viral death protein Apoptin interacts with Hippi, the protein interactor of Huntingtin-interacting protein 1. Biochem. Biophys. Res. Commun. 305, 359-364 (2003).
26. Teodoro JG, Heilman DW, Parker AE, Green MR: The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 18, 1952-1957 (2004).
27. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M: Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J. Cell Sci. 118, 4485-4493 (2005).
28. Liu X, Zeidan YH, Elojeimy S et al.: Involvement of sphingolipids in apoptin-induced cell killing. Mol. Ther. 14, 627-636 (2006).
29. Liu X, Elojeimy S, El-Zawahry AM et al.: Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol. Ther. 14, 637-646 (2006).
30. Danen-Van Oorschot AAAM, Van der Eb AJ, Noteborn MHM: Bcl-2 stimulates apoptin-induced apoptosis. Adv. Exp. Med. Biol. 457, 245-249 (1999).
31. Burek M, Maddika S, Burek CJ et al.: Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent. Oncogene 25, 2213-2222 (2006).
32. Lin CF, Chen CL, Lin YS: Ceramide in apoptotic signaling and anticancer therapy. Curr. Med. Chem. 13, 1609-1616 (2006).
33. Heilman DW, Green MR, Teodoro JG: The anaphase promoting complex: a critical target for viral proteins and anticancer drugs. Cell Cycle 4, 560-563 (2005).
34. Kornitzer D, Sharf R, Kleinberger T: Adenovirus E4orf4 protein induces PP2A-dependent growth arrest in Sacharomyces cerevislae and interacts with the anaphase-promoting complex/cyclosome. J. Cell. Biol. 23, 331-344 (2001).
35. Chauhan D, Li G, Hideshima T et al.: Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of bortezomib/proteasome inhibitor PS-341. Oncogene 23, 3597-3602 (2004).
36. Olijslagers SJ, Zhang YH, Backendorf C, Noteborn MH: Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin. Pharmacol. Toxicol. 100, 127-131 (2007).
37. Zhang YH, Olijslagers S, Backendorf C. Noteborn HM: Apoptin close-ups: perspectives towards novel therapies. J. Med. Mol. Biol. 3, 401-406 (2006).
38. Li X, Jin N, Mi Z. et al.: Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Int. J. Cancer 119, 2948-2957 (2006).
39. Pietersen A: Preclinical studies with apoptin. PhD thesis. Erasmus University Rotterdam. The Netherlands (2003).
40. Pietersen AM, van der Eb MM, Rademaker HJ et al.: Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther. 6, 882-892 (1999).
41. van der Eb MM, Pietersen AM, Speetjens FM et al.: Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther. 9, 53-61 (2002).
42. Lian H, Jin N, Li X et al.: Induction of an effective antitumor immune response and tumor regression by combined administration of IL-18 and Apoptin. Cancer Immunol. Immunother. 56, 181-192 (2007).
43. Gommans WM, McLaughlin PM, Schalk JA, Groothuis GM, Haisma HJ, Rots MG: Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter. J. Control Release 117, 1-10 (2007).
44. Peng DJ, Sun J, Wang YZ et al.: Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther. 14, 66-73 (2007)
45. Kooistra K, Zhang YH, Henriquez NV, Weiss B, Mumberg D, Noteborn MH: TT virus-derived apoptosis-inducing protein induces apoptosis preferentially in hepatocellular carcinoma-derived cells. J. Gen. Virol. 85, 1445-1450 (2004).
46. Markowski-Grimsrud CJ, Schat KA: Infection with chicken anaemia virus impairs the generation of pathogen-specific cytotoxic T lymphocytes. Immunology 109, 283-294 (2003).
47. Noteborn MH: Chicken anemia virus induced apoptosis: underlying molecular mechanisms. Vet. Microbiol. 98, 89-94 (2004).
48. Kamada K, Kuroishi A, Kamahora T, Kabat P, Yamaguchi S, Hino S: Spliced mRNAs detected during the life cycle of chicken anemia virus. J. Gen. Virol. 87, 2227-2233 (2006).
49. Islam MR, Johne R, Raue R, Todd D, Muller H: Sequence analysis of the full-length cloned DNA of a chicken anaemia virus (CAV) strain from Bangladesh: evidence for genetic grouping of CAV strains based on the deduced VP1 amino acid sequences. J. Vet. Med. B. Infect. Dis. Vet. Public Health 49, 332-337 (2002).
50. Peters MA, Crabb BS, Washington EA, Browning GF: Site-directed mutagenesis of the VP2 gene of chicken anemia virus affects virus replication, cytopathollogy and host-cell MHC class I expression. J. Gen. Virol. 87, 823-831 (2006).
51. Jeffrey KL, Camps M, Rommel C, Mackay CR: Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 6, 391-403 (2007).